

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
NDA ACCEPTED BY NMPA FOR THE NEW INDICATION OF
ANAPRAZOLE SODIUM FOR THE TREATMENT OF
REFLUX ESOPHAGITIS

The board of directors (the “**Board**”) of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the New Drug Application (“**NDA**”) for Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei (安久衛®)), a Class 1 innovative drug independently developed by the Company, for the treatment of adult reflux esophagitis (“**RE**”) has been formally accepted by the National Medical Products Administration (“**NMPA**”) recently.

The acceptance of the NDA is based on the results of a Phase III registration clinical study conducted in Mainland China, which was a multi-centre, randomized, double-blind, double-dummy, active-controlled trial. The study used rabeprazole sodium as the active control, and the primary efficacy endpoint was the investigator-assessed endoscopic healing rate of RE at Week 8. Results showed that the healing rate was 88.4% (95% CI: 84.3%–92.5%) in the anaprazole sodium 60 mg group versus 84.6% (95% CI: 80.0%–89.2%) in the rabeprazole sodium 20 mg group, with a rate difference of 3.8% (95% CI: -2.4%–10.0%). The trial met its predefined primary endpoint, and the healing rate in the anaprazole sodium group was numerically higher than that in the control group.

Reflux esophagitis is a common subtype of gastroesophageal reflux disease characterized by mucosal erosion and damage, with typical symptoms of heartburn and regurgitation that severely impair patients’ quality of life. Recurrent episodes may lead to complications including esophageal stricture and Barrett’s esophagus. According to China Insights Consultancy data, the prevalence of RE in China remained high, increasing from 36.7 million in 2018 to 38.3 million in 2024, and is projected to reach 42.4 million in 2032, representing a large and growing clinical demand. RE is the second indication for which an NDA has

been submitted for anaprazole sodium following duodenal ulcer, and is meaningful to fully unlocking its clinical value as a next-generation proton pump inhibitor. Upon approval, it is expected to provide a new and effective acid-suppressive treatment option for patients with RE, further enhancing the product's competitiveness and commercial potential.

ABOUT ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei (安久衛®)) was approved for marketing by the NMPA of China in June 2023 for the treatment of patients with duodenal ulcer. Anaprazole Sodium features an innovative structural design with characteristics including non-enzymatic plus multi-enzymatic metabolism and balanced intestinal-renal dual-channel excretion, with only 3.5% metabolized through CYP2C19, making it unaffected by CYP2C19 gene polymorphism. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium has lower risk of drug-drug interactions, making it a safer choice for patients on multiple medications and those with renal impairment, and is a proton pump inhibitor more suitable for the Chinese population. As a Class 1 innovative drug in China, Anaprazole Sodium fills the gap in domestically developed proton pump inhibitors, bringing treatment options with both superior efficacy and safety to Chinese patients. In addition to the approved indication of duodenal ulcer and the RE indication for which NDA is accepted for review herein, the Phase III clinical study in China of Anaprazole Sodium Enteric-coated Tablets for the eradication of *Helicobacter pylori* has recently successfully completed first patient dosing.

This announcement is a voluntary announcement made by the Company for the purpose of keeping its shareholders and potential investors informed of the Group's latest business developments and does not contain any advertisement or intention regarding the use of any drugs, surgical equipment, treatments, or oral products.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, 30 June, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.